Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in ...
Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013
T cells engineered with chimeric antigen receptor targeting CD19 produce signifi...
Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA
T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence ( Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013
Removal of alpha/beta T cells and of CD19 B cells in children With acute leuka...
Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy
Removal of alpha/beta  T cells and of CD19  B cells in children With acute leukaemia ( Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy )
8 Dec 2013
Transplantation and short telomeres increase the risk of cognitive impairment
Dr Smita Bhatia - City of Hope National Medical Center, Duarte, California
Transplantation and short telomeres increase the risk of cognitive impairment ( Dr Smita Bhatia - City of Hope National Medical Center, Duarte, California )
8 Dec 2013
Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regre...
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
7 Dec 2013
Encouraging outcomes in older patients following nonmyeloablative haploidentical...
Dr Yvette Kasamon - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Encouraging outcomes in older patients following nonmyeloablative haploidentical blood or marrow transplantation ( Dr Yvette Kasamon - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
7 Dec 2013
Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome a...
Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherl...
Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction ( Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherlands )
3 Dec 2013
Cancer cells and the immune system: a natural story?
Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France
Cancer cells and the immune system: a natural story? ( Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France )
3 Dec 2013
Why are Immuno-Oncology compounds different?
Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Why are Immuno-Oncology compounds different? ( Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
3 Dec 2013
Immuno-Oncology: a concept or already a reality?
Prof. Peter Johnson - Cancer Research UK Centre, University of Southampton, UK
Immuno-Oncology: a concept or already a reality? ( Prof. Peter Johnson - Cancer Research UK Centre, University of Southampton, UK )
3 Dec 2013
Lgr5 stem cells in self-renewal and cancer
Dr Hans Clevers - Hubrecht Institute, Utrecht, Netherlands
Lgr5 stem cells in self-renewal and cancer ( Dr Hans Clevers - Hubrecht Institute, Utrecht, Netherlands )
3 Oct 2013
ecancermedicalscience Editor's Choice for October 2013
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience Editor's Choice for October 2013 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
25 Sep 2013